Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors

Metastatic pancreatic ductal adenocarcinomas (PDACs) are now more effectively controlled using chemotherapy combinations such as FOLFIRINOX and gemcitabine plus nab-paclitaxel (NabP) regimens with a subset of patients who achieve a sustained tumor stabilization or response. The next challenge is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammel, Pascal, Vitellius, Carole, Boisteau, Émeric, Wisniewski, Mathilde, Colle, Elise, Hilmi, Marc, Dengremont, Christelle, Granier, Sandra, Turpin, Anthony, de Mestier, Louis, Neuzillet, Cindy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350045/
https://www.ncbi.nlm.nih.gov/pubmed/32695234
http://dx.doi.org/10.1177/1758835920937949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350045/
https://www.ncbi.nlm.nih.gov/pubmed/32695234
http://dx.doi.org/10.1177/1758835920937949

Ejemplares similares